NCT06476860

Brief Summary

ARDS is a pulmonary edema injury. Among its etiologies, it can be secondary to septic shock. Managing septic shock involves hemodynamic optimization with significant fluid and sodium inputs. Fluid and sodium inputs in ARDS worsen respiratory failure through capillary leakage, and a restrictive input strategy is clinically beneficial (reduced mechanical ventilation duration and ICU stay). Predicting ARDS onset in septic shock allows for optimized fluid and sodium input management, adopting a restrictive rather than liberal approach to minimize deterioration in respiratory function.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2023

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 23, 2023

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

May 30, 2024

Completed
2 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2024

Completed
26 days until next milestone

First Posted

Study publicly available on registry

June 27, 2024

Completed
Last Updated

June 27, 2024

Status Verified

May 1, 2024

Enrollment Period

1 year

First QC Date

May 30, 2024

Last Update Submit

June 21, 2024

Conditions

Keywords

proteinuriaseptic shocksepsisAcute Respiratory Distresse Syndrome

Outcome Measures

Primary Outcomes (1)

  • Measurement of proteinuria in the first 24 hours (H0 and H24) of septic shock.

    relationship between proteinuria kinetics in the first 24 hours (H0 and H24) of septic shock and presence of ARDS at H72

    24 hours

Secondary Outcomes (3)

  • measurement of albuminuria urinary IgG at H0 and H24

    24 hours

  • measurement of alpha-1-microglobulin at H0 and H24

    24 hours

  • measurement of urinary IgG at H0 and H24

    24 hours

Study Arms (1)

patients suspected of sepsis or septic shock

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All adult patients suspected of sepsis or septic shock until 100 patients are enrolled. Infection diagnosis is based on systemic clinical signs (fever) or local inflammatory signs, biological evidence, and suspicion or confirmation of an infectious agent. The diagnosis of sepsis involves infection accompanied by organ failure, which may manifest as cardiovascular, respiratory, neurological, metabolic, renal, coagulation, or hepatic impairment. These signs may precede hypotension or occur without it.

You may qualify if:

  • All patients aged 18 and older admitted to the intensive care unit for suspected sepsis or septic shock.

You may not qualify if:

  • Minors or opposition to participation.
  • Chronic dialysis patients
  • Organ transplant recipients
  • Confirmed urinary tract infection
  • Subject with macroscopic hematuria
  • Pregnant woman

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHI Andre Gregoire

Montreuil, 93100, France

Location

Related Publications (1)

  • Iba T, Levy JH. Derangement of the endothelial glycocalyx in sepsis. J Thromb Haemost. 2019 Feb;17(2):283-294. doi: 10.1111/jth.14371. Epub 2019 Feb 3.

MeSH Terms

Conditions

SepsisShock, SepticProteinuria

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShockUrination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrological ManifestationsSigns and Symptoms

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2024

First Posted

June 27, 2024

Study Start

May 23, 2023

Primary Completion

June 1, 2024

Study Completion

June 1, 2024

Last Updated

June 27, 2024

Record last verified: 2024-05

Locations